UY30535A1 - Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones. - Google Patents

Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.

Info

Publication number
UY30535A1
UY30535A1 UY30535A UY30535A UY30535A1 UY 30535 A1 UY30535 A1 UY 30535A1 UY 30535 A UY30535 A UY 30535A UY 30535 A UY30535 A UY 30535A UY 30535 A1 UY30535 A1 UY 30535A1
Authority
UY
Uruguay
Prior art keywords
antirretroviral
pharmacos
applications
preparation process
composition
Prior art date
Application number
UY30535A
Other languages
English (en)
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of UY30535A1 publication Critical patent/UY30535A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion proporciona: - Composicion oral solida comprendiendo uno o más fármacos antirretrovirales, por ejemplo, inhibidores de proteasa como el lopinavir, ritonavir o una combinacion de estos con uno o más excipientes, o con al menos un polímero insoluble en agua, en donde 1 a relacion de fármaco a polímero en la composicion está en el intervalo de aproximadamente 1: 1 hasta alredodor de 1:6, - Composicion que es más pequena para la cantidad correspondiente del principio activo, que además posee propiedad de enmascaramiento del sabor - Proceso para la elaboracion de las composiciones.
UY30535A 2006-08-10 2007-08-10 Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones. UY30535A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1269MU2006 2006-08-10
IN1227MU2007 2007-06-27

Publications (1)

Publication Number Publication Date
UY30535A1 true UY30535A1 (es) 2008-03-31

Family

ID=38667164

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30535A UY30535A1 (es) 2006-08-10 2007-08-10 Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.

Country Status (9)

Country Link
US (1) US20100173921A1 (es)
AU (1) AU2007283196A1 (es)
BR (1) BRPI0714265A2 (es)
CA (1) CA2660374A1 (es)
CL (1) CL2007002331A1 (es)
PE (1) PE20080422A1 (es)
TW (1) TW200815033A (es)
UY (1) UY30535A1 (es)
WO (1) WO2008017867A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037398A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
PL2487161T3 (pl) 2007-02-23 2017-03-31 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
SG190618A1 (en) 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
HUE030800T2 (en) * 2008-10-07 2017-05-29 Astrazeneca Uk Ltd Pharmaceutical Form No. 514
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
US20130142877A1 (en) 2010-05-10 2013-06-06 Evonik Roehm Gmbh Pharmaceutical dosage form comprising one or more antiretroviral active ingredients
MY171941A (en) 2010-11-24 2019-11-08 Melinta Subsidiary Corp Pharmaceutical compositions
GB201118182D0 (en) * 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
WO2013131646A1 (en) * 2012-03-07 2013-09-12 Ratiopharm Gmbh Dosage form comprising lopinavir and ritonavir
MX2014013326A (es) 2012-05-03 2015-08-10 Cipla Ltd Composición antirretroviral.
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
WO2014080365A1 (en) * 2012-11-23 2014-05-30 Ranbaxy Laboratories Limited Method of reducing an unpleasant odor of a pharmaceutical composition
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
CN103550993B (zh) * 2013-10-30 2015-07-08 王维玲 一种大气污染洁净剂及制备方法、洁净剂的应用及应用方法
PL3250182T3 (pl) * 2015-01-27 2023-07-31 Janssen Pharmaceutica Nv Kompozycje dyspergowalne
RU2744270C2 (ru) * 2015-12-28 2021-03-04 ЭсЭсПи КО., ЛТД., ДЖАПАН Прессованный фармацевтический препарат
GB2625584A (en) * 2022-12-21 2024-06-26 Rb Health Us Llc Novel composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
MXPA03009971A (es) * 2001-05-03 2004-02-12 Hoffmann La Roche FORMA DE DOSIFICACIoN FARMACEUTICA DE MESILATO DE NELFINAVIR AMORFO.
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
BRPI0707465B8 (pt) * 2006-02-03 2022-07-05 Evonik Roehm Gmbh composições farmacêuticas compreendendo misturas de polímeros e ingredientes ativos dificilmente solúveis em água, seu uso e seus processos de preparação, forma farmacêutica e seu processo de produção

Also Published As

Publication number Publication date
US20100173921A1 (en) 2010-07-08
TW200815033A (en) 2008-04-01
BRPI0714265A2 (pt) 2013-04-16
PE20080422A1 (es) 2008-04-28
CL2007002331A1 (es) 2008-04-18
CA2660374A1 (en) 2008-02-14
WO2008017867A3 (en) 2009-04-16
WO2008017867A2 (en) 2008-02-14
AU2007283196A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
UY30535A1 (es) Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
GT200700034A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
AR105712A1 (es) Composiciones de insulina de rápida acción
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
CR11285A (es) Composicion farmaceutica que contiene un antagonista del canal de calcio de tipo dihipropiridina y metodo para la prepacion de la misma
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
BR112016026667A8 (pt) comprimido oralmente desintegrante para administração de avanafil, métodos associados de fabricação e uso de um inibidor de pde v
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
CL2022002531A1 (es) Moduladores de nlrp3
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
AR070392A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de eleboracion
AR062925A1 (es) Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
CL2017002229A1 (es) Inhibidores de bace1.
MX2022001802A (es) Metodos para incrementar la biodisponibilidad de medicamentos farmaceuticos y de venta libre.
ECSP22092205A (es) Composición farmacéutica acuosa de levilimab y su uso
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
BRPI1010987B8 (pt) composições de dosagem sólida de liberação controlada contendo ibuprofeno
UY39503A (es) Formulación sólida

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20190815